Clockwork Bio has been established as a pioneering AI-native biotechnology company dedicated to advancing early-stage oncology drug discovery. The firm is developing a platform that focuses on modelling and controlling cell state transitions, aiming to overcome the limitations encountered in current drug discovery pipelines, particularly in relation to complex and heterogeneous diseases such as cancer.
The company was founded by Shane Lewin and Nick Peterson, both of whom previously dedicated six years to their roles at GSK. Clockwork Bio is addressing what an increasing number of researchers are referring to as cancer’s core data problem. Traditional drug discovery pipelines have proven most effective in diseases characterised by distinct genetic mutations, often identified through genome-wide association studies or extensive screening processes.
However, in the field of oncology, tumours are not merely static lesions but dynamic populations of cells that accumulate mutations, adapt to various treatments, communicate with neighbouring cells, and interact continuously with the immune system. Capturing this complex behaviour necessitates the integration of multiple layers of data simultaneously, which include pathology, sequencing, spatial biology, treatment histories, and clinical outcomes.
This intricacy is also a significant reason why standard drug discovery pipelines frequently encounter challenges in oncology, where disease states are often influenced less by a single molecular driver and more by factors such as epigenetic regulation, signalling pathways, and the broader cellular context.
The consequences of this complexity are evident in the low success rates and exorbitant costs associated with early-stage target discovery programmes in oncology. Such programmes are reported to take between four to seven years and incur costs of approximately £30 million, yet they progress to clinical trials with a mere 3.6% probability of approval.
Clockwork Bio’s innovative approach is centred on generating and learning from controlled transitions between healthy and diseased cell states in vitro. The platform is said to integrate several recent advancements in technology, including:
- Active learning systems that design and execute experiments iteratively.
- AI-based phenotyping techniques that quantify differences between cellular states.
- Emerging therapeutic modalities capable of modulating cell behaviour with enhanced precision.
The overarching goal of Clockwork Bio is to develop systems that can both induce disease-relevant states in cells and reverse them, all while continuously learning the underlying biological principles. This marks a significant shift from the traditional focus on static target identification to a more dynamic modelling of disease processes.
Generally, the application of AI in oncology has begun to evolve beyond mere scan reading and pathology support. There is a growing trend towards systems that unify pathology, sequencing, spatial biology, treatment histories, and clinical outcomes into a comprehensive framework.
For the time being, Clockwork Bio is operating in stealth mode, with a formal product launch and further updates anticipated in 2026.